These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 6438046)

  • 1. In-vitro activity of enoxacin against aminoglycoside-resistant gram-negative bacilli and other clinical isolates.
    Duncan IB; Skulnick M; Marshall PW
    J Antimicrob Chemother; 1984 Sep; 14 Suppl C():1-6. PubMed ID: 6438046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of enoxacin compared with norfloxacin and amikacin.
    van der Auwera P; de Moor G; Lacroix G; Mambour A; Rossion N; Schuyteneer F
    Eur J Clin Microbiol; 1985 Feb; 4(1):55-8. PubMed ID: 3157568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The comparative in-vitro activity of eight newer quinolones and nalidixic acid.
    King A; Phillips I
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():1-20. PubMed ID: 3468100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The comparative in-vitro activity of norfloxacin, ciprofloxacin, enoxacin and nalidixic acid against 423 strains of gram-negative rods and staphylococci isolated from infected hospitalised patients.
    Guimaraes MA; Noone P
    J Antimicrob Chemother; 1986 Jan; 17(1):63-7. PubMed ID: 2936708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative antimicrobial activity of enoxacin, ciprofloxacin, amifloxacin, norfloxacin and ofloxacin against 177 bacterial isolates.
    Bassey CM; Baltch AL; Smith RP
    J Antimicrob Chemother; 1986 May; 17(5):623-8. PubMed ID: 2941401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative in vitro activities of enoxacin (CI-919, AT-2266) and eleven antipseudomonal agents against aminoglycoside-susceptible and -resistant Pseudomonas aeruginosa strains.
    Bassey CM; Baltch AL; Smith RP; Conley PE
    Antimicrob Agents Chemother; 1984 Sep; 26(3):417-8. PubMed ID: 6439116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-vitro activity of pefloxacin compared to enoxacin, norfloxacin, gentamicin and new beta-lactams.
    Clarke AM; Zemcov SJ; Campbell ME
    J Antimicrob Chemother; 1985 Jan; 15(1):39-44. PubMed ID: 3156112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The in-vitro activity of CI-934 compared with that of other new 4-quinolones and nalidixic acid.
    King A; Shannon K; Slegg J; Phillips I
    J Antimicrob Chemother; 1986 Aug; 18(2):163-9. PubMed ID: 3463557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enoxacin: worldwide in-vitro activity against 22451 clinical isolates.
    Siporin C; Towse G
    J Antimicrob Chemother; 1984 Sep; 14 Suppl C():47-55. PubMed ID: 6594322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activities of enoxacin and 17 other antimicrobial agents against multiply resistant, gram-negative bacteria.
    Rudrik JT; Cavalieri SJ; Britt EM
    Antimicrob Agents Chemother; 1984 Jul; 26(1):97-100. PubMed ID: 6591853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enoxacin: in-vitro and animal evaluation as a parenteral and oral agent against hospital bacterial isolates.
    Heifetz CL; Bien PA; Cohen MA; Dombrowski ME; Griffin TJ; Malta TE; Sesnie JC; Shapiro MA; Wold SA
    J Antimicrob Chemother; 1988 Feb; 21 Suppl B():29-42. PubMed ID: 3129392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The activity of enoxacin against clinical bacterial isolates in comparison with that of five other agents, and factors affecting that activity.
    Reeves DS; Bywater MJ; Holt HA
    J Antimicrob Chemother; 1984 Sep; 14 Suppl C():7-17. PubMed ID: 6594324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-vitro activity of enoxacin, ofloxacin, norfloxacin and nalidixic acid.
    Bauernfeind A; Ullmann U
    J Antimicrob Chemother; 1984 Sep; 14 Suppl C():33-8. PubMed ID: 6238931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of sisomicin, an aminoglycoside antibiotic, against clinical isolates.
    Stewart D; Bodey GP
    J Antibiot (Tokyo); 1975 Feb; 28(2):149-55. PubMed ID: 234415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-vitro activity of newer quinolones against aerobic bacteria.
    Auckenthaler R; Michéa-Hamzehpour M; Pechère JC
    J Antimicrob Chemother; 1986 Apr; 17 Suppl B():29-39. PubMed ID: 2940214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A laboratory assessment of ciprofloxacin and comparable antimicrobial agents.
    Shrire L; Saunders J; Traynor R; Koornhof HJ
    Eur J Clin Microbiol; 1984 Aug; 3(4):328-32. PubMed ID: 6237900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro antibacterial activity of enoxacin (CI-919).
    Fernandes CJ; Munro R; Toohey M; Shanker S; Mallon R; Daley D; Harland GS; Stevens DA; Wilson RD; Ackerman VP
    Pathology; 1986 Apr; 18(2):240-2. PubMed ID: 3093961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The in-vitro activities of enoxacin and ofloxacin compared with that of ciprofloxacin.
    King A; Shannon K; Phillips I
    J Antimicrob Chemother; 1985 May; 15(5):551-8. PubMed ID: 3159712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of CI-934 compared with ciprofloxacin, enoxacin, norfloxacin, and vancomycin.
    Floyd-Reising SA; Kelley SG; Hindler JA; Young LS
    Diagn Microbiol Infect Dis; 1987 Apr; 6(4):301-6. PubMed ID: 3472704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Laboratory evaluation of enoxacin: comparison with norfloxacin and nalidixic acid.
    Teoh-Chan CH; Cowlishaw A; Eley A; Slater G; Greenwood D
    J Antimicrob Chemother; 1985 Jan; 15(1):45-52. PubMed ID: 3156113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.